Benzinga | Jan 11, 2021 07:04AM EST

Ultragenyx Pharma Provides Crysvita Sales Guidance Updates

Crysvita revenue in Ultragenyx territories for the year ended December 31, 2020 is approximately $137 million to $139 million. This is at the top end of the guidance range of $130 million to $140 million that was provided during the third quarter financial results and at the beginning of 2020, despite COVID-19 impact.

For 2021, Crysvita revenue in the Ultragenyx territories is estimated to be between $180 million and $190 million.